Hyper-activation of the PI3K/mTOR pathway is known to be involved in leukemia and drug resistance.25 The gene expression data suggested an enrichment of the PI3K/mTOR pathway in the resistant cell lines, as well as in primary patient AML blasts, which are resistant to sorafenib therapy. This evidence concerns the gene MTOR and leukemia.